Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest.
Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest.
复制标题
DOI：
10.3892/ijo.2018.4407
复制
发表时间：
2018-08
影响因子：
5.2
通讯作者：
Shukla S
中科院分区：
文献类型：
--
作者：
Oak C;Khalifa AO;Isali I;Bhaskaran N;Walker E;Shukla S
薯蓣皂苷是一种植物黄酮类化合物，具有抗前列腺癌细胞增殖和抗癌作用。在这项研究中，使用蛋白质印迹分析的蛋白质表达和流式细胞术的细胞周期分析，我们确定，治疗的LNCaP和PC-3前列腺癌细胞与薯蓣皂苷导致细胞周期蛋白D1，Cdk 2和Cdk 4的表达水平显着下降（这些蛋白质在细胞周期的G 0-G1期保持活性）。这些变化伴随着c-Myc和Bcl-2表达的减少，以及Bax，p27 Kip 1和FOXO 3a蛋白表达的增加，这表明薯蓣皂苷对蛋白质转录的潜在调节作用。用薯蓣皂苷处理前列腺癌细胞通过抑制X连锁凋亡抑制剂（XIAP）和增加裂解的PARP和裂解的半胱天冬酶-3表达水平来启动凋亡机制。总的来说，这项研究的结果提供了一个深入的分析的分子机制，负责调控作用的薯蓣皂苷对关键分子，扰乱细胞周期，抑制细胞生长，并建议薯蓣皂苷可能被证明是一种有效的抗癌药物用于治疗前列腺癌的未来。
Diosmetin, a plant flavonoid, has been shown to exert promising effects on prostate cancer cells as an anti-proliferative and anticancer agent. In this study, using western blot analysis for protein expression and flow cytometry for cell cycle analysis, we determined that the treatment of the LNCaP and PC-3 prostate cancer cells with diosmetin resulted in a marked decrease in cyclin D1, Cdk2 and Cdk4 expression levels (these proteins remain active in the G0-G1 phases of the cell cycle). These changes were accompanied by a decrease in c-Myc and Bcl-2 expression, and by an increase in Bax, p27Kip1 and FOXO3a protein expression, which suggests the potential modulatory effects of diosmetin on protein transcription. The treatment of prostate cancer cells with diosmetin set in motion an apoptotic machinery by inhibiting X-linked inhibitor of apoptosis (XIAP) and increasing cleaved PARP and cleaved caspase-3 expression levels. On the whole, the findings of this study provide an in-depth analysis of the molecular mechanisms responsible for the regulatory effects of diosmetin on key molecules that perturb the cell cycle to inhibit cell growth, and suggest that diosmetin may prove to be an effective anticancer agent for use in the treatment of prostate cancer in the future.
登录
查看更多内容
临床抗癌药物开发：靶向细胞周期蛋白依赖性激酶。
影响因子：
8.8
作者：
Benson, C;Kaye, S;Workman, P;Garrett, M;Walton, M;de Bono, J
通讯作者：
de Bono, J
影响因子：
16.6
作者：
Dong, Peng;Maddali, Manoj V.;Srimani, Jaydeep K.;Thelot, Francois;Nevins, Joseph R.;Mathey-Prevot, Bernard;You, Lingchong
通讯作者：
You, Lingchong
影响因子：
9.9
作者：
Eijkelenboom, Astrid;Mokry, Michal;Burgering, Boudewijn M. T.
通讯作者：
Burgering, Boudewijn M. T.
影响因子：
5.6
作者：
Androutsopoulos, Vasilis P.;Spandidos, Demetrios A.
通讯作者：
Spandidos, Demetrios A.
影响因子：
4.8
作者：
Hawksworth, D.;Ravindranath, L.;Petrovics, G.
通讯作者：
Petrovics, G.